plumbagin has been researched along with Malignant Melanoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alem, FZ; Bejaoui, M; Isoda, H; Rhourri-Frih, B; Villareal, MO | 1 |
| Gowda, R; Robertson, GP; Sharma, A | 1 |
| Gowda, R; Kardos, G; Robertson, GP; Sharma, A; Singh, S | 1 |
| Chen, R; Jiang, P; Li, J; Li, Y; Lu, J; Peng, R; Shen, Q; Zhang, L | 1 |
| Chang, JK; Chiang, YM; Hsu, YL; Kuo, PL; Sung, SC; Wang, CC | 1 |
5 other study(ies) available for plumbagin and Malignant Melanoma
| Article | Year |
|---|---|
Elucidation of the effect of plumbagin on the metastatic potential of B16F10 murine melanoma cells via MAPK signalling pathway.
Topics: Animals; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Melanoma; Melanoma, Experimental; Mice; Naphthoquinones; Neoplasm Invasiveness; Neoplasm Metastasis; Oligonucleotide Array Sequence Analysis; Plant Extracts; Signal Transduction; Wound Healing | 2020 |
Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclins; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Humans; Melanoma; Mice, Nude; Naphthoquinones; Signal Transduction; Skin Neoplasms; STAT3 Transcription Factor; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Compounding; Drug Stability; Drug Synergism; Female; Humans; Liposomes; Melanoma; Mice; Nanoparticles; Naphthoquinones; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Plumbagin enhances TRAIL-mediated apoptosis through up-regulation of death receptor in human melanoma A375 cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Humans; Melanoma; Naphthoquinones; Receptors, TNF-Related Apoptosis-Inducing Ligand; Skin Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2010 |
Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Glutathione; Humans; Inhibitory Concentration 50; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinase 5; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Naphthoquinones; Neoplastic Stem Cells; Phosphorylation; Reactive Oxygen Species; Signal Transduction; Time Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2008 |